The Cancer Genomics and Tumor Immunotherapy Symposium: A Clinical Perspective is a key educational event, jointly hosted by the Cancer Genomics Program (CGP) and the Tumor Immunotherapy Program (TIP) at the Princess Margaret Cancer Centre. The objective of this Symposium is to provide a clinical and translational perspective on cancer genomics and tumor immunotherapy by highlighting emerging therapies and technologies as they apply to precision cancer medicine at the point of care. Participants will learn about new research on mechanisms of resistance and response, emerging therapies and technologies aimed at increasing the personalized approach to treatment, and genomic applications in the clinic.

This one-day symposium will be a hybrid event this year, held both in-person and virtually.


Confirmed speakers include:

Vinod Balachandran, MD, Memorial Sloan Kettering Cancer Center

Federico Gaiti, PhD, Princess Margaret Cancer Centre

Alexander Wyatt, PhD, Vancouver Prostate Centre

Anna Spreafico, MD, PhD, Princess Margaret Cancer Centre

George Zogopoulos, MD, PhD, McGill University

Loretta Nastoupil, MD, MD Anderson Cancer Center

Logan Walsh, PhD, McGill University 

Andy Minn, MD, PhD, University of Pennsylvania


Target Audience for the 2023 Cancer Genomics and Tumor Immunotherapy Symposium:

  • Oncologists: Medical, Radiation, Surgical
  • Pathologists
  • Clinical Geneticists
  • Genetic Counselors
  • Laboratory Directors
  • Laboratory Technicians
  • Oncology Nurses
  • Bioinformaticians
  • Basic and Translational Scientists
  • Basic, Translational and Clinical Trainees
  • Pharmaceutical Representatives


Topics to be discussed in a presentation or panel include:

  • Pancreatic Cancer - exceptional survivors to RNA vaccines 
  • Deciphering the determinants of hematopoietic clonal outgrowth using single-cell multi-omics
  • Genomics and epigenomic evolution in serial ctDNA from metastatic prostate cancer
  • Updates on Cellular Therapy, Lessons Learned from Large B-cell Lymphoma
  • Unraveling Single-Cell Spatial Landscapes of Lung and Brain Tumor Immune Microenvironments using Artificial Intelligence
  • Tumor Microenvironment
  • Debate: Cancer interception in molecular residual disease will improve survival in many solid tumors